Background: Elevated level of serum uric acid (SUA) is frequently considered as one of the risk factors for ischaemic stroke. Hyperuricemia has been shown to have a positive association with cardiovascular morbidity and mortality.
Materials and Methods: 60 cases of both sexes with acute ischemic stroke were recruited in this study. 30 patients were on anti-platelet therapy and 30 didn't have anti-platelet therapy. Serum uric acid levels were correlated with the anti-platelet therapy in these patients.
Results: After eliminating the confounders, the patients who were on anti-platelet therapy had reduced uric acid levels and it was found to be statistically significant (p = 0.000).
Conclusion: Serum uric acid is elevated in acute phase of ischaemic stroke patients and it is associated with mortality in all patients even after adjusting the confounders. In this present study, it has been found that patients who were on anti-platelet therapy have normal uric acid levels.
Keywords: Serum uric acid, acute ischaemic stroke, antiplatelet therapy, hyperuricemia, cardiovascular morbidity.
How to cite this article: Gopan AGP, Ramkumar M, Ananthakumar PK, Aamir SA, Rajasekhar S, Rajasekaran M. Association of serum uric acid level in acute ischaemic stroke patients on antiplatelet therapy compared to those who are not on antiplatelet therapy. Int J Drug Deliv Technol. 2026;16(6s): 117-123; DOI: 10.25258/ijddt.16.6s.14
Source of support: Nil.
Conflict of interest: None